Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
Eli Lilly has been hit with a subpoena from the New York Attorney General's Office over the pricing and sales of its insulin products, the drugmaker disclosed in a filing with the Securities and Exchange Commission on Friday.
Attorney general offices in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada are also seeking information on its pricing, Eli Lilly said in the filing. It also received a civil investigative demands from attorney general offices in Washington and New Mexico.
Eli Lilly did not respond to requests for comment.
Earlier this week, drugmaker Sanofi disclosed that it, Eli Lilly and Novo Nordisk had received subpoena from New York's AG.
Eli Lily, the maker of blockbuster diabetes treatment Humalog, and other manufacturers have been under scrutiny from U.S. lawmakers and the White House over the high cost of insulin, a 100-year-old life-saving medication.
The Centers for Disease Control and Prevention estimates more than 30 million Americans have diabetes. The annual cost of insulin for people with Type 1 diabetes in the U.S. nearly doubled from 2012 to 2016 to $5,700 from $2,900, according to an analysis by the nonprofit Health Care Cost Institute. Eli Lilly's Humalog makes $3 billion in annual sales.
Members of Congress launched an investigations earlier this year into rising cost of insulin, seeking information from Eli Lilly and other manufacturers on price increases.
Drug companies have instead placed blamed on pharmacy benefit managers, sometimes called middlemen, for the sticker shock some patients see at the counter. Drugmakers argue that PBMs should pass the rebates negotiated with manufactures along to patients.
Additionally, Eli Lilly has said its products' net price, the total paid after factoring in rebates and discounts, has actually decreased over the years.
In a preemptive move, Eli Lilly launched earlier this year a half-price version of Humalog. The rebranded product called Insulin Lispro is $137.35 per vial.